** Shares of Edgewise Therapeutics rise about 17% to $32.28 in premarket trading
** Company says its experimental genetic disorder drug met the main goal in a mid-stage study
** The drug, sevasemten, is being developed to treat Becker Muscular Dystrophy, a rare condition that results in progressive muscle weakness and degeneration
** Sevasemten helped significantly reduce levels of creatine kinase, an enzyme associated with skeletal muscle damage in the study- EWTX
** Up to last close, stock more than doubled YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。